Life Technologies Invests in Synthetic Genomics | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Life Technologies announced after the close of the market on Wednesday that it has made an equity investment in Synthetic Genomics, the firm behind research by Craig Venter and colleagues that resulted in the first functional bacterial cells controlled by a synthetic genome.

Terms of the investment were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.